Integrated Platform Technology Oncalis proprietary cell-based High-Throughput Screening (HTS) for kinase inhibitors enables the rapid identification of hits with drug-like properties Oncalis proprietary cell-based High-Throughput Screening (HTS) for kinase inhibitors is a yeast cell-based screening platform that enables functional assays to identify early "drug-like" inhibitors of Receptor Tyrosine Kinases (RTKs), cytoplasmic kinases, proteases and protein-protein interactions. Yeast cellular systems for functional screenings combine rapidity and specificity with in vivo biological relevance. What are the advantages of Oncalis cell-based HTS for kinase inhibitors?
Hence, Oncalis cell-based High-Throughput Screening (HTS) for kinase inhibitors reduces the time and investment usually spent on in vitro assays of molecules that must be abandoned at the "final" stage of cellular proof of concept. How can you benefit from Oncalis cell-based HTS for RTK inhibitors? Oncalis is offering its cell-based High-Throughput Screening (HTS) for kinase inhibitors for a fee for service. This fee is on a per-well basis. The HTS can be pan-hits (i.e. screening of numerous hits for selected kinases) or pan-kinases (i.e. screening of limited number of hits for all or a large panel of kinases). For information or offer contact:
Oncalis AG Biotech Center Zurich
|